Journal of Clinical Oncology, Vol 16, 3392-3397, Copyright © 1998 by American Society of Clinical Oncology
Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study
L Sengelov, C Kamby, B Lund and SA Engelholm
Department of Oncology, Herlev University Hospital, Denmark. lisa.sengelov@dadlnet.dk
PURPOSE: Docetaxel and cisplatin has documented single-agent activity and
different toxicity profiles in patients with metastatic urothelial cancer.
We performed a phase II study in which docetaxel was combined with
cisplatin to evaluate response rate, toxicity, and survival. PATIENTS AND
METHODS: Eligibility criteria included performance status (World Health
Organization [WHO]) less than 3; normal bone marrow, liver, and renal
function; and no concurrent malignancy or symptomatic peripheral
neuropathy. Docetaxel (Taxotere; Rhone-Poulenc Rorer, Paris, France) 75
mg/m2 was combined with cisplatin 75 mg/m2 every third week. Patients
received premedication with prednisolone and clemastine. RESULTS: A total
of 25 patients were assessable for response and toxicity. Median age was 64
years; five patients had locoregional disease only and 20 had metastatic
disease. Response was achieved in 15 patients (60%; 95% confidence interval
[CI], 39% to 79%), including seven patients (26%) who achieved a complete
response. Overall median survival time was 13.6 months (range, 1.5 to
26.4+). The most frequent toxicity was nausea and vomiting (80% of
patients). Neutropenia grade 3 or 4 was observed in 56% of patients, but
only one had febrile neutropenia. Mucositis and diarrhea were encountered
in 13% of cycles, mostly grade 1 or 2. Peripheral neuropathy and skin
changes grade 1 and 2 were observed in 76% and 36%, respectively. Fluid
retention and hypersensitivity reactions were infrequent and mild.
CONCLUSION: The combination of docetaxel and cisplatin is effective and
feasible in patients with metastatic urothelial cancer with a manageable
safety profile.
This article has been cited by other articles:
|
|
|
|
 
I Boukovinas, N Androulakis, L Vamvakas, P Papakotoulas, N Ziras, A Polyzos, A Kalykaki, A Kotsakis, N Xenidis, I Gioulmbasanis, et al.
Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group
Ann. Onc.,
November 1, 2006;
17(11):
1687 - 1692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bamias, I. Tiliakos, M.-D. Karali, and M. A. Dimopoulos
Systemic chemotherapy in inoperable or metastatic bladder cancer
Ann. Onc.,
April 1, 2006;
17(4):
553 - 561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Galsky
The Role of Taxanes in the Management of Bladder Cancer
Oncologist,
November 1, 2005;
10(10):
792 - 798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bamias, G. Aravantinos, C. Deliveliotis, D. Bafaloukos, C. Kalofonos, N. Xiros, A. Zervas, D. Mitropoulos, E. Samantas, D. Pectasides, et al.
Docetaxel and Cisplatin With Granulocyte Colony-Stimulating Factor (G-CSF) Versus MVAC With G-CSF in Advanced Urothelial Carcinoma: A Multicenter, Randomized, Phase III Study From the Hellenic Cooperative Oncology Group
J. Clin. Oncol.,
January 15, 2004;
22(2):
220 - 228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Pectasides, J. Glotsos, N. Bountouroglou, A. Kouloubinis, N. Mitakidis, N. Karvounis, N. Ziras, and A. Athanassiou
Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial
Ann. Onc.,
February 20, 2002;
13(2):
243 - 250.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Bellmunt, V. Guillem, L. Paz-Ares, J. L. Gonzalez-Larriba, J. Carles, E. Batiste-Alentorn, A. Saenz, M. Lopez-Brea, A. Font, M. Nogue, et al.
Phase I-II Study of Paclitaxel, Cisplatin, and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium
J. Clin. Oncol.,
September 18, 2000;
18(18):
3247 - 3255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
